The relative value of disease management programs versus drug manufacturer rebates.
Curtiss
Frederic R
FR
D003362:Cost-Benefit Analysis; D019468:Disease Management; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D005431:Florida; D006801:Humans; D008329:Managed Care Programs / Q000191:economics; D004364:Pharmaceutical Preparations / Q000191:economics; D015397:Program Evaluation / Q000191:economics*
D004364:Pharmaceutical Preparations